Black Friday saleUp to 70% OFF
CRISPR THERAPEUTICS LTDCRISPR THERAPEUTICS LTDCRISPR THERAPEUTICS LTD

CRISPR THERAPEUTICS LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

1CG chart


Full chart

1CG upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.11 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.52 EUR
Net income (FY)
‪−139.17 M‬ EUR
Revenue (FY)
‪336.32 M‬ EUR
Shares float
‪81.67 M‬
Beta (1Y)
1.50

Employees


Employees (FY)
407
Change (1Y)
−51 −11.14%
Revenue / Employee (1Y)
‪912.05 K‬ EUR
Net income / Employee (1Y)
‪−377.42 K‬ EUR

About CRISPR Therapeutics AG


Sector
Health Technology
Industry
Biotechnology
CEO
Samarth Kulkarni
Website
crisprtx.com
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00F39Q1B0
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

1CG news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 1CG is 40.00 EUR — it hasn't changed in the past 24 hours. Watch CRISPR THERAPEUTICS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CRISPR THERAPEUTICS LTD stocks are traded under the ticker 1CG.
We've gathered analysts' opinions on CRISPR THERAPEUTICS LTD future price: according to them, 1CG price has a max estimate of 189.76 EUR and a min estimate of 28.61 EUR. Watch 1CG chart and read a more detailed CRISPR THERAPEUTICS LTD stock forecast: see what analysts think of CRISPR THERAPEUTICS LTD and suggest that you do with its stocks.
1CG reached its all-time high on May 24, 2018 with the price of 63.50 EUR, and its all-time low was 11.94 EUR and was reached on Jun 1, 2017. View more price dynamics on 1CG chart.
See other stocks reaching their highest and lowest prices.
1CG stock is 0.00% volatile and has beta coefficient of 1.50. Track CRISPR THERAPEUTICS LTD stock price on the chart and check out the list of the most volatile stocks — is CRISPR THERAPEUTICS LTD there?
Today CRISPR THERAPEUTICS LTD has the market capitalization of ‪4.11 B‬, it has decreased by −4.28% over the last week.
Yes, you can track CRISPR THERAPEUTICS LTD financials in yearly and quarterly reports right on TradingView.
CRISPR THERAPEUTICS LTD is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
1CG earnings for the last quarter are −0.91 EUR per share, whereas the estimation was −1.24 EUR resulting in a 27.06% surprise. The estimated earnings for the next quarter are −1.16 EUR per share. See more details about CRISPR THERAPEUTICS LTD earnings.
CRISPR THERAPEUTICS LTD revenue for the last quarter amounts to ‪540.68 K‬ EUR, despite the estimated figure of ‪5.90 M‬ EUR. In the next quarter, revenue is expected to reach ‪7.44 M‬ EUR.
1CG net income for the last quarter is ‪−77.19 M‬ EUR, while the quarter before that showed ‪−118.01 M‬ EUR of net income which accounts for 34.59% change. Track more CRISPR THERAPEUTICS LTD financial stats to get the full picture.
No, 1CG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTICS LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTICS LTD EBITDA is ‪−281.13 M‬ EUR, and current EBITDA margin is −54.61%. See more stats in CRISPR THERAPEUTICS LTD financial statements.
Like other stocks, 1CG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTICS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTICS LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTICS LTD stock shows the buy signal. See more of CRISPR THERAPEUTICS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.